Authorized purpose: SIS System fuses clinical brain MRI with postoperative CT to visualize DBS anatomy, localize STN, GPe, GPi, and Vim, and segment implanted leads for surgical review.
Clinical role
Brain-image registration, segmentation, quantification, visualization, or procedure-planning support.
Images and patients
Radiological images; modality varies or is not specified in FDA list · Brain
Key limitation
Keep in mind: The SIS System can be used in conjunction with other clinical methods as an aid in visualization and location; its output supplements information from standard clinical methods with additional, adjunctive information.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: SIS System fuses clinical brain MRI with postoperative CT to visualize DBS anatomy, localize STN, GPe, GPi, and Vim, and segment implanted leads for surgical review.
Which images or clinical context are in scope?Modality: Radiological images; modality varies or is not specified in FDA list Anatomy or clinical context: Brain Input: The patient's own clinical MR image and postoperative CT images in which implanted leads are visible.
Who uses it?Intended users: Medical professionals, including but not limited to surgeons, neurologists and radiologists.
What does the software produce?Output: A patient-specific 3D anatomical model of specific brain structures, with implanted leads located and identified in relation to the brain structure of interest.
What is its most important limitation?Key limitation: The SIS System can be used in conjunction with other clinical methods as an aid in visualization and location; its output supplements information from standard clinical methods with additional, adjunctive information.
Clinical takeaway. Clinical role: SIS System fuses clinical brain MRI with postoperative CT to visualize DBS anatomy, localize STN, GPe, GPi, and Vim, and segment implanted leads for surgical review.
Evidence takeaway. Evidence from the reviewed source record: K241083 reports manufacturer registration, localization, segmentation, and software validation for the expanded Vim workflow.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
SIS System fuses clinical brain MRI with postoperative CT to visualize DBS anatomy, localize STN, GPe, GPi, and Vim, and segment implanted leads for surgical review.
Exact FDA submission
Checked 2026-09-19
Clinical-use display mirrors the exact FDA-supported purpose reconciled from the decision-summary packet.
The patient's own clinical MR image and postoperative CT images in which implanted leads are visible.
Exact FDA submission
Checked 2026-09-19
The exact device description specifies clinical MR input and postoperative CT images for visible implanted leads; it does not establish associated clinical workflow data.
A patient-specific 3D anatomical model of specific brain structures, with implanted leads located and identified in relation to the brain structure of interest.
Exact FDA submission
Checked 2026-09-19
The exact device description supports the 3D anatomical model and lead localization/identification, not the dossier's broad list of alerts, maps and reports.
Medical professionals, including but not limited to surgeons, neurologists and radiologists.
Exact FDA submission
Checked 2026-09-19
The exact indication names medical professionals and these example roles; it does not establish the broader qualified and trained staff list in the dossier.
The SIS System can be used in conjunction with other clinical methods as an aid in visualization and location; its output supplements information from standard clinical methods with additional, adjunctive information.
Exact FDA submission
Checked 2026-09-19
These are the exact adjunctive-use boundaries in the indication and technological characteristics; the packet does not state the dossier's additional modality, protocol, lesion or longitudinal-comparison limits.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
K241083 reports manufacturer registration, localization, segmentation, and software validation for the expanded Vim workflow.
Sensitivity is not the primary endpoint for this acquisition, reconstruction, segmentation, guidance, or quantitative function. Use the task-specific evidence below.
Reported specificity
Not applicable
Not applicable
Not applicable
Checked 2026-09-03
Specificity is not the primary endpoint for this acquisition, reconstruction, segmentation, guidance, or quantitative function. Use the task-specific evidence below.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
K241083 FDA performance package for SIS System
DesignManufacturer software, registration, segmentation, and localization validation
PopulationDBS planning and postoperative review using brain MRI and CT
Scopeexact submission
Tested versionSIS System release adding Vim localization
IndependenceSponsor or vendor study
K241083
Manufacturer evidence submitted for clearance or approval; local clinical, technical, and workflow acceptance remains necessary.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K241083 by exact submission identifier. This does not exclude product-family or later safety information.
Public source
Exact FDA submission
Checked 2026-09-03
Exact-identifier review does not prove absence of all product-family safety signals.
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging, procedural, or surgical service line and verify payer, site-of-service, and coding assumptions independently.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: The patient's own clinical MR image and postoperative CT images in which implanted leads are visible.
Scope: Exact FDA submission. The exact device description specifies clinical MR input and postoperative CT images for visible implanted leads; it does not establish associated clinical workflow data.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: DICOM import and output to PACS, workstations, or surgical systems; validate series selection, orientation, registration, measurements, routing, latency, and failure handling.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: A patient-specific 3D anatomical model of specific brain structures, with implanted leads located and identified in relation to the brain structure of interest.
Scope: Exact FDA submission. The exact device description supports the 3D anatomical model and lead localization/identification, not the dossier's broad list of alerts, maps and reports.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: A patient-specific 3D anatomical model of specific brain structures, with implanted leads located and identified in relation to the brain structure of interest.
Scope: Exact FDA submission. The exact device description supports the 3D anatomical model and lead localization/identification, not the dossier's broad list of alerts, maps and reports.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
DICOM import and output to PACS, workstations, or surgical systems; validate series selection, orientation, registration, measurements, routing, latency, and failure handling.
Only qualified radiologists, neurologists, neurosurgeons, and trained imaging or surgical staff. should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
Monitor by exact hardware, software and model version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track these product-specific limits: Outputs are adjunctive and require review against source images and clinical context; modality, protocol, registration, lesion, anatomy, and longitudinal-comparison limits apply.
DICOM import and output to PACS, workstations, or surgical systems; validate series selection, orientation, registration, measurements, routing, latency, and failure handling.
exact submission · checked 2026-09-03
Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.
Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Outputs are adjunctive and require review against source images and clinical context; modality, protocol, registration, lesion, anatomy, and longitudinal-comparison limits apply.
exact submission · checked 2026-09-03
Define stop-use, escalation, rollback, and revalidation triggers before production use.
Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.
product family · checked 2026-09-03
Vendor productivity claims are scenario inputs, not guaranteed local savings.
Monitor by exact hardware, software and model version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track these product-specific limits: Outputs are adjunctive and require review against source images and clinical context; modality, protocol, registration, lesion, anatomy, and longitudinal-comparison limits apply.
exact submission · checked 2026-09-03
Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
Radiological images; modality varies or is not specified in FDA list
FDA source
Exact FDA submission
Checked 2026-09-19
The exact device description identifies the patient's clinical MR image and postoperative CT images; it does not support the dossier's modality-unspecified wording. Controlled directory display reconciled from exact FDA wording: Clinical MR and postoperative CT imaging. -> Radiological images; modality varies or is not specified in FDA list.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
27Fields reviewed
11Source classes checked
10Screened PubMed leads
5Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains 10 PubMed and 5 ClinicalTrials.gov candidate records. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 10 PubMed and 5 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, fda decision material, reimbursement policy, fda device recall, fda decision summary packet, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not publicly available - checked 2026-09-03 - Exact FDA submission
No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, enabled features, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not verified - checked 2026-09-03 - Exact FDA submission
Public materials reviewed for this exact release do not establish the complete security posture. Request data-flow, identity, audit, encryption, retention, remote-access, vulnerability-management, backup, and incident-response evidence.
Authorized purpose: Cercare Neurosuite with Capillary Function and Oncology Virtual Expert processes CT or MR information to provide perfusion, tissue-blood-volume, diffusion, labeling, and quantification support for adult brain glioma workflows.
Modality
Radiological images; modality varies or is not specified in FDA list
Authorized purpose: Quantitative brain MRI and amyloid-PET analysis, including volumetric reference-percentile comparison and SUVR quantification, to support physician clinical evaluation.
Modality
Radiological images; modality varies or is not specified in FDA list
Authorized purpose: SIS System fuses clinical brain MRI with postoperative CT to visualize DBS anatomy, localize STN, GPe, and GPi, and segment implanted leads for professional review.
Modality
Radiological images; modality varies or is not specified in FDA list
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.